Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Vertex Pharmaceuticals Inc
Pfizer Inc.
Eli Lilly & Co.
Moderna, Inc. Common Stock
Intellia Therapeutics, Inc
Amgen Inc
Gilead Sciences Inc
Merck & Co., Inc.
Vir Biotechnology, Inc. Common Stock
ABBVIE INC.
The chart shows the growth of an initial investment of $10,000 in Regeneron Pharmaceuticals Inc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Regeneron Pharmaceuticals Inc (REGN) has returned -1.60% so far this year and 33.85% over the past 12 months. Looking at the last ten years, REGN has achieved an annualized return of 6.56%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Regeneron Pharmaceuticals Inc (REGN) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.24% | 6.65% | 0.20% | -1.70% | ||||||||
| 2025 | -6.64% | 4.48% | -9.64% | -5.04% | -16.87% | 6.91% | 4.10% | -0.40% | -3.15% | 14.18% | 18.67% | -0.48% |
| 2024 | 7.88% | 2.17% | -0.52% | -7.68% | 10.20% | 7.23% | 3.06% | 11.67% | -10.82% | -20.48% | -11.18% | -5.02% |
| 2023 | 5.07% | 1.09% | 8.13% | -2.08% | -8.48% | -2.37% | 4.48% | 10.99% | -1.39% | -5.70% | 5.09% | 6.47% |
| 2022 | -2.63% | 1.73% | 13.49% | -6.09% | 1.18% | -11.71% | -1.03% | -0.08% | 19.26% | 6.15% | 0.23% | -4.59% |
| 2021 | 3.49% | -12.14% | 4.10% | 1.97% | 3.92% | 10.44% | 3.24% | 16.68% | -10.31% | 10.96% | -0.54% | -1.19% |
| 2020 | -10.60% | 30.88% | 9.73% | 8.62% | 16.90% | 3.08% | 1.13% | -2.35% | -9.07% | -3.37% | -5.33% | -6.37% |
| 2019 | 16.60% | 0.52% | -5.56% | -16.82% | -12.05% | 3.94% | -4.05% | -5.42% | -4.08% | 10.46% | 19.42% | 1.98% |
| 2018 | -3.38% | -12.61% | 7.49% | -11.32% | -0.86% | 14.49% | 6.69% | 10.91% | -0.36% | -16.53% | 7.86% | 0.27% |
| 2017 | -3.11% | 4.11% | 2.52% | 0.13% | 18.07% | 6.77% | -0.52% | 2.12% | -10.26% | -10.19% | -10.39% | 5.50% |
| 2016 | 0.73% | 5.55% | -12.42% | 21.81% | -7.65% | 1.84% | -14.18% | 9.76% | -3.26% |
The charts below present risk-adjusted performance metrics for Regeneron Pharmaceuticals Inc (REGN) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of REGN compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Regeneron Pharmaceuticals Inc volatility is 1.75%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 40.56B | 37.76B | 33.08B | 29.21B | 25.43B | 17.16B | 14.81B | 11.73B | 8.76B | 6.97B | 5.61B | 3.87B | 2.95B | 2.08B | 1.32B |
| Equity Attributable To Parent (USD) | 31.26B | 29.35B | 25.97B | 22.66B | 18.77B | 11.03B | 11.09B | 8.76B | 6.14B | 4.45B | 3.65B | 2.54B | 1.95B | 1.25B | 485.73M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 31.26B | 29.35B | 25.97B | 22.66B | 18.77B | 11.03B | 11.09B | 8.76B | 6.14B | 4.45B | 3.65B | 2.54B | 1.95B | 1.25B | 485.73M |
| Noncurrent Liabilities (USD) | 4.93B | 4.46B | 3.68B | 3.41B | 2.73B | 3.44B | 1.62B | 1.53B | 1.48B | 1.28B | 1.14B | 674.84M | 700.10M | 671.56M | 689.58M |
| Other Current Liabilities (USD) | 2.66B | 2.51B | 2.20B | 2.05B | 2.93B | 1.76B | 1.33B | 962.80M | 943.66M | 1.09B | 677.94M | 561.88M | 229.41M | 143.56M | 105.44M |
| Wages (USD) | 773.00M | 640.90M | 618.20M | 497.30M | 440.70M | 465.80M | 344.40M | 261.80M | 191.83M | 153.09M | 133.22M | 92.78M | 69.43M | 19.99M | 42.84M |
| Accounts Payable (USD) | 939.00M | 789.50M | 606.60M | 589.20M | 564.00M | 475.50M | 418.10M | 218.20M | - | - | - | - | - | - | - |
| Current Liabilities (USD) | 4.37B | 3.94B | 3.42B | 3.14B | 3.93B | 2.70B | 2.10B | 1.44B | 1.14B | 1.24B | 811.16M | 654.66M | 298.84M | 163.55M | 148.27M |
| Liabilities (USD) | 9.30B | 8.41B | 7.11B | 6.55B | 6.67B | 6.14B | 3.72B | 2.98B | 2.62B | 2.52B | 1.95B | 1.33B | 998.94M | 835.11M | 837.85M |
| Other Non-current Assets (USD) | 21.28B | 17.95B | 12.56B | 12.41B | - | - | - | 2.71B | 2.07B | 1.71B | 1.10B | 730.06M | 627.10M | 494.54M | 302.75M |
| Intangible Assets (USD) | 1.26B | 1.15B | 1.04B | 915.50M | - | - | - | - | - | - | - | - | - | - | - |
| Fixed Assets (USD) | - | - | - | - | - | - | - | 2.58B | 2.36B | 2.08B | 1.59B | 974.31M | 526.98M | 379.94M | 367.96M |
| Noncurrent Assets (USD) | 22.54B | 19.10B | 13.60B | 13.33B | 11.42B | 7.38B | 7.12B | 5.29B | 4.43B | 3.79B | 2.69B | 1.70B | 1.15B | 874.48M | 670.71M |
| Other Current Assets (USD) | 14.82B | 15.57B | 16.90B | 13.48B | 12.06B | 7.86B | 6.27B | 5.30B | 3.61B | 2.78B | 2.68B | 2.04B | 1.73B | 1.18B | - |
| Inventory (USD) | 3.20B | 3.09B | 2.58B | 2.40B | 1.95B | 1.92B | 1.42B | 1.15B | 726.14M | 399.36M | 238.58M | 128.86M | 70.35M | 28.64M | - |
| Current Assets (USD) | 18.02B | 18.66B | 19.48B | 15.88B | 14.01B | 9.78B | 7.69B | 6.45B | 4.34B | 3.18B | 2.92B | 2.17B | 1.80B | 1.21B | 652.88M |
| Assets (USD) | 40.56B | 37.76B | 33.08B | 29.21B | 25.43B | 17.16B | 14.81B | 11.73B | 8.76B | 6.97B | 5.61B | 3.87B | 2.95B | 2.08B | 1.32B |
AstraZeneca released positive Phase 3 trial data for tozorakimab in COPD patients, showing the drug reduced moderate-to-severe exacerbations compared to placebo and met primary endpoints across broad patient groups. The stock gained 3.68% in premarket trading. The company forecasts peak annual sales of $3-5 billion for the drug, positioning it competitively in the COPD market against rivals like Regeneron and Sanofi's Dupixent.
Regeneron is recovering from recent headwinds including patent loss for Eylea, with shares up 35% over six months. While the company shows promise through key products like Dupixent, pipeline candidates in weight loss and gene therapy, and the improved Eylea HD formulation, its $79 billion market cap makes it unlikely to deliver the exceptional returns needed to turn average investors into multimillionaires. The stock is expected to deliver respectable returns over the next decade but will likely match S&P 500 performance rather than significantly outperform.
Sanofi and Regeneron announced that Dupixent (dupilumab) has received marketing authorization in Japan for treating moderate-to-severe bullous pemphigoid in adults. The approval was based on the LIBERTY-BP-ADEPT study showing over four times more Dupixent patients achieved sustained disease remission compared to placebo (18% vs. 4%). This marks the seventh approved indication for Dupixent in Japan.
Dupixent (dupilumab), developed by Sanofi and Regeneron, has received approval in Japan as the first targeted medicine for treating moderate to severe bullous pemphigoid in adults. The approval is based on pivotal Phase 2/3 trial data showing over four times more patients achieved sustained disease remission with Dupixent compared to placebo at week 36. This marks the seventh indication approved for Dupixent in Japan.
CytomX Therapeutics priced a $250 million underwritten public offering of 45.99 million shares at $5.30 per share and pre-funded warrants. The company plans to use net proceeds for development of Varseta-M and other pipeline programs. The offering is expected to close on March 19, 2026.
While several pharmaceutical companies have posted encouraging clinical data for weight-loss drugs that could challenge Eli Lilly's market-leading Zepbound, most won't reach the U.S. market for years. Eli Lilly maintains its dominance through strong pipeline candidates like orforglipron and retatrutide, diversified revenue streams, and AI investments in drug discovery. The company's 2025 revenue grew 45% year-over-year, positioning it to remain the biggest beneficiary of the expanding weight-loss market.
Regeneron Pharmaceuticals and Society for Science announced the 2026 Regeneron Science Talent Search winners, with Connor Hill winning the top $250,000 award for his work on noble polyhedra. The competition awarded over $1.8 million to 40 finalists for innovative STEM research. Regeneron renewed its title sponsorship through 2036, committing an additional $150 million to support the next generation of science and technology leaders.
Regeneron Pharmaceuticals announced the 2026 Science Talent Search winners, with Connor Hill from Pennsylvania winning the top $250,000 award for discovering noble polyhedra. The competition awarded over $1.8 million to 40 finalists for innovative STEM research. Regeneron extended its title sponsorship through 2036 with an additional $150 million commitment, bringing total support to over $300 million through 2036.
The Lamzede market is experiencing significant growth driven by advancements in rare disease diagnostics, expansion of enzyme replacement therapies, and increased focus on personalized medicine for genetic disorders. Europe leads the market in 2025 while Asia-Pacific shows the fastest growth potential, though tariffs present cost challenges. Lamzede, used to treat alpha-mannosidosis, exemplifies progress in enzyme replacement therapy development.
The article recommends two biotech companies as strong portfolio additions in 2026. Regeneron Pharmaceuticals is highlighted for its blockbuster drugs Dupixent and Eylea HD showing strong sales growth, along with a rich pipeline in multiple therapeutic areas, trading at a reasonable 17x forward earnings. Vertex Pharmaceuticals is praised as the leading cystic fibrosis treatment player with strong intellectual property protection and recent expansion into gene-editing and pain management, trading at 24x forward earnings.